Biohaven Ltd
BHVN
Company Profile
Business description
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. Its products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.
Contact
215 Church Street
New HavenCT06510
USAT: +1 203 404-0410
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2024
Employees
239
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,604.10 | 52.90 | 0.62% |
CAC 40 | 7,613.05 | 29.32 | 0.39% |
DAX 40 | 19,657.37 | 73.98 | 0.38% |
Dow JONES (US) | 43,275.91 | 36.86 | 0.09% |
FTSE 100 | 8,358.25 | 26.88 | -0.32% |
HKSE | 20,502.35 | 301.76 | -1.45% |
NASDAQ | 18,489.55 | 115.94 | 0.63% |
Nikkei 225 | 38,954.60 | 27.15 | -0.07% |
NZX 50 Index | 12,923.22 | 99.33 | 0.77% |
S&P 500 | 5,864.67 | 23.20 | 0.40% |
S&P/ASX 200 | 8,344.40 | 61.20 | 0.74% |
SSE Composite Index | 3,269.17 | 7.60 | 0.23% |